Brigatinib-associated autoimmune hepatitis: A case report.

Buyuksimsek, Mahmut; Ogul, Ali; Yetisir, Abdullah Evren; Duman, Berna Bozkurt; Tohumcuoglu, Mert; Cil, Timucin; Koseci, Tolga; Kidi, Mehmet Mutlu; Sumbul, Hilmi Erdem

Buyuksimsek, Mahmut; Ogul, Ali; Yetisir, Abdullah Evren; Duman, Berna Bozkurt; Tohumcuoglu, Mert; Cil, Timucin; Koseci, Tolga; Kidi, Mehmet Mutlu; Sumbul, Hilmi Erdem.

Afiliação

Buyuksimsek M; Department of Medical Oncology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
Ogul A; Department of Medical Oncology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
Yetisir AE; Department of Medical Oncology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
Duman BB; Department of Medical Oncology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
Tohumcuoglu M; Department of Medical Oncology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
Cil T; Department of Medical Oncology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
Koseci T; Department of Medical Oncology, Cukurova University, Adana, Turkey.
Kidi MM; Department of Medical Oncology, Cukurova University, Adana, Turkey.
Sumbul HE; Department of Internal Medicine, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.

J Oncol Pharm Pract ; : 10781552231171322, 2023 Apr 18.

Article em En | MEDLINE | ID: mdl-37073439

Palavras-chave

ALK; Autoimmune hepatitis; ROS1; brigatinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: J Oncol Pharm Pract Assunto da revista: FARMACIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Turquia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google